
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2021

Commission File Number: 001-38396

BIOFRONTERA AG

(Registrant's name / Translation of registrant's name into English)

Hemmelrather Weg 201, D-51377 Leverkusen Germany
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form:40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A

EXHIBITS

Exhibit Number	Description
99.1	Biofrontera Aktiengesellschaft Leverkusen 6 % convertible bond 2017/2022 DE000A2BPDE6.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOFRONTERA AG

By: /s/ Hermann Lübbert

Name: Hermann Lübbert

Title: Chief Executive Officer

Date: March 16, 2021

-CONVENIENCE TRANSLATION-

Biofrontera Aktiengesellschaft

Leverkusen

6 % convertible bond 2017/2022

DE000A2BPDE6.

Adjustment of the conversion price

The 6 % convertible bond 2017/2022 of Biofrontera AG (“Company”) is divided into bearer bonds with a nominal amount of EUR 100 each (“2017/2022 Bond”). Pursuant to the terms and conditions of the 2017/2022 Bonds (“2017/2022 Terms and Conditions”), each bondholder has the right to convert each 2017/2022 Bond into no-par value registered common shares of the Company (“Shares”). On March 13, 2018, the Company announced that the conversion price, after adjustment, will be EUR 4.75 per share. The Company subsequently announced on August 27, 2020, that following a further adjustment, the conversion price per share would be EUR 4.737 per share.

On February 05, 2021, the Company published a subscription offer for up to 8,969,870 new no-par value registered shares with a notional share in the capital stock of EUR 1.00 each based on the capital increase resolved by the Annual General Meeting on May 28, 2020. The shareholders were granted the statutory subscription right. A total of 8,969,870 new shares were issued.

Section 11 of the 2017/2022 Terms and Conditions provides for the creditors of the 2017/2022 Bond to be protected against dilution in this case. The conversion price was therefore to be reduced in accordance with the 2017/2022 Terms and Conditions by the amount corresponding to the value of the subscription right granted to one share for the up to 8,969,870 new no-par value registered shares.

The Company hereby announces that the conversion price of the 2017/2022 Bonds will therefore be reduced by **EUR 0.021** to **EUR 4.716 per share** in accordance with the 2017/2022 Terms and Conditions.

Leverkusen, March 2021

Biofrontera Aktiengesellschaft

The Management Board
